Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning agreements with the FDA regarding endpoints and clinical trial design and anticipated clinical, other product development activities and timing of these activities and the adequacy of existing financial resources. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, statements of the Company's ability to gain FDA agreement on protocol design and time frames to do so, the strength of the combined oncology product pipeline, the adequacy of financial resources, the timing of clinical trials and development efforts and the results of clinical and pre-clinical studies are all forward-looking statements. The potential risks and uncertainties include, among others, the possibility that an agreement with FDA cannot be reached regarding a clinical trial using pain as the primary endpoint for OGX-011, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier clinical trial results, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2007 and its most re
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a ... regenerative medicine, announced today that it will host ... on Tuesday, July 29, 2014, at 4:30 p.m. ... an overview of Asterias, business strategy and product ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the ...
(Date:7/24/2014)... have yet to materialise. Yet, scientists are making ... computers faster. One such approach relies on quantum ... applying an electric field. A new study demonstrates ... quantum dots (TQDs) with electrical impulses can help ... should TQDs be used as quantum information units, ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study of ... study of the structure and functions of proteomes or ... tools and technology. Genomics involves the mapping of genes ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... NEW YORK, April 16 NexGenix Pharmaceuticals, presented,data ... Annual Meeting of the AACR,in San Diego today. ... on NXD30001, one of several novel, radicicol-based,Hsp90 inhibitors ... in breast cancer tumor xenograft models,without evidence for ...
... April 16 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... inhibitors demonstrating a high degree of target,specificity, strong ... tumor,tissue and significant antitumor activity and safety in ... protein chaperone that acts to stabilize and/or activate ...
... ROCKVILLE, Md., April 16 The Board of ... that Dr. Danong Chen has,been elected as the ... Chen,was previously the President and CEO of Tanox ... by Genentech in 2007.,Previously Dr. Chen was Vice-President ...
Cached Biology Technology:NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4Danong Chen appointed CEO of Theranostics Health 2
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
(Date:7/24/2014)... disturbance has different effects on different species of ... Universities of Bristol and Exeter which tested fish ... to a flying seagull predator model when exposed ... in European minnows. , Lead author Dr ... said: "Noise levels in many aquatic environments have ...
(Date:7/24/2014)... June 24, 2014 Some sticky research out of ... against a certain species of toxic grass fungus: moose ... month,s Biology Letters , "Ungulate saliva inhibits a ... applied to red fescue grass (which hosts a fungus ... in slower fungus growth and less toxicity. , "Plants ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Moose drool inhibits growth of toxic fungus: York U research 2
... set of proteins found in our intestines can recognize and ... surfaces, scientists at Emory University School of Medicine have discovered. ... scheduled to appear in the journal Nature Medicine . ... on the surfaces of bacteria, but these proteins are different ...
... remember the muscle shirts we wore in our teens and 20s? ... usually is obsolete. Yes, at the big 4-0 we begin to ... it may be gone. It,s an inevitable process of aging called ... A study conducted in mice with accelerated muscle loss at The ...
... scientists at the University of Missouri Center for Agroforestry ... can trap and break down veterinary antibiotics in manure ... can be effective in protecting water quality, controlling erosion ... beauty of it," said Keith Goyne, assistant professor of ...
Cached Biology News:Bacteria-killing proteins cover blood type blind spot 2Bacteria-killing proteins cover blood type blind spot 3Muscle loss finding may one day save physiques 2Plant buffers may limit spread of antibiotics in animal waste 2
... The thermostable dUTPase(pyrococcus fruriosus) ... (using proofreading DNA polymerases). It ... reactions and dNTP solutions. The ... DNA polymerase reaction can prevent dUTP ...
... AVOID FREEZE/THAW CYCLES. An assay kit designed ... Western blotting. PARP is an enzyme implicated ... apoptosis, PARP is cleaved by caspase-3. Cleavage ... to 85 kDa is a hallmark of ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Many other sizes and custom ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
Biology Products: